Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2013

View Archived Issues

The Korea Institute of Ocean Science and Technology synthesizes novel agents for cancer

Vertex Pharmaceuticals discloses new agents for influenza

New agents that inhibit AIMP2-DX2 selected by Korean researchers

XOMA-3AB well tolerated in phase I study

Tulane University researchers describe B. pseudomallei vaccine strategy

Takeda Pharmaceutical synthesizes new inhibitors of ROR gamma t

Dainippon Sumitomo Pharma divulges new neutrophil elastase inhibitors

Pooled phase Ib results for dupilumab show efficacy in atopic dermatitis

Second phase III trial of tavaborole in onychomycosis meets endpoints

Cubist Pharmaceuticals obtains QIDP and fast track designations for late-stage antibiotic candidates

FluoroPharma Medical reports data from phase II CardioPET study

Kythera Biopharmaceuticals presents phase III results for ATX-101

Adventrx Pharmaceuticals to change name, provides update on ANX-188

BioAlliance Pharma signs agreement with global vaccine company

Progen signs licensing agreement for PG-545

Pseudomonas-specific antibiotic POL-7080 completes phase I study

Novo Nordisk launches new long-acting insulin Tresiba in Denmark

Santhera considering strategic options following decisions regarding Catena and Raxone

NeuroDerm completes phase I study of levodopa/carbidopa patch pump

Enrollment completed in phase II study of PsiOxus' MT-102 for cancer cachexia

FDA approves revised SPA for phase III trial of Collategene in critical limb ischemia

FDA approves expanded indication for Corifact

miRNAs as novel targets in androgen-independent prostate cancer

UCLA receives funding to identify genetic changes that affect the severity of DMD

Companies partner to advance allosteric modulators targeting adenosine A2A receptor

Alere receives Gates Foundation grant to develop tuberculosis assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...